Search
OCREVUS 300 MG / ML, Solution à diluer pour perfusion
Details
| --- | Description |
|---|---|
| Pack | 1 flacon |
| Strength (Dosage) | 300 MG / ML |
| Laboratory | ROCHE S.A |
| Ingredients | Ocrélizumab |
| Therapeutic class | Immunosuppresseur, anticorps monoclonal humanisé (anti-CD20) |
| ATC code | L04AA36 |
| PPH | $5,505.70 |
| PPV | $5,615.00 |
| Refundable | No |
| Refund base | $0.00 |
| Refund rate | $0.00 |
| Table | A |
| Marketing status | Commercialized |
| Type | Not specified |
| Uses | Sclérose en plaques récurrente-rémittente active ou primaire progressive |
| Warnings | |
| Dosage | |
| Avoid | |
| Side effects | |
| Interactions |
Medications from the same laboratory
Disclaimer
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
The materials provided by this website, https://www.doctolist.com, are for informational purposes only and are not provided as legal advice or medical advice. No reader should act on the basis of this material without seeking appropriate professional advice with respect to the particular facts and applicable law. The materials are not presented as correct, complete or up-to-date, and are not a substitute for a visit or consultation with a physician or health professional.
Report a problem